Literature DB >> 1721390

Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression.

R J Schmidt1, K K Venkat, F Dumler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721390

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.

Authors:  P S Randhawa; R Shapiro; M L Jordan; T E Starzl; A J Demetris
Journal:  Am J Surg Pathol       Date:  1993-01       Impact factor: 6.394

3.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

4.  Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy.

Authors:  P S Randhawa; A C Tsamandas; M Magnone; M Jordan; R Shapiro; T E Starzl; A J Demetris
Journal:  Am J Surg Pathol       Date:  1996-03       Impact factor: 6.394

5.  Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.

Authors:  Vinod Baburaj Pandirikkal; Manoj Jain; Sanjeev Gulati
Journal:  Pediatr Nephrol       Date:  2006-11-23       Impact factor: 3.714

6.  Dangerous drug interactions leading to hemolytic uremic syndrome following lung transplantation.

Authors:  Haralabos Parissis; Kate Gould; John Dark
Journal:  J Cardiothorac Surg       Date:  2010-09-02       Impact factor: 1.637

7.  Bone marrow hypoplasia complicating tacrolimus (FK506) therapy.

Authors:  Annamaria Nosari; Laura Marbello; Luciano G De Carlis; Andrea De Gasperi; Giuliana Muti; Valentina Mancini; Enrica Morra
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.